<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - CO-TRIMOXAZOLE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>CO-TRIMOXAZOLE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of susceptible infections</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                960 mg twice daily.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                960 mg every 12 hours, increased to 1.44 g every 12 hours, increased dose used in severe infection.</li>
              <li class="dose child"><strong>For children 6 weeks&#8211;5 months</strong><br/>
                120 mg twice daily, alternatively 24 mg/kg twice daily.</li>
              <li class="dose child"><strong>For children 6 months&#8211;5 years</strong><br/>
                240 mg twice daily, alternatively 24 mg/kg twice daily.</li>
              <li class="dose child"><strong>For children 6&#8211;11 years</strong><br/>
                480 mg twice daily, alternatively 24 mg/kg twice daily.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                960 mg twice daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of <ph outputclass="organism"> <i>Pneumocystis jirovecii</i> </ph> (<ph outputclass="organism"> <i>Pneumocystis carinii</i> </ph> ) infections (undertaken where facilities for appropriate monitoring available&#8212;consult microbiologist and product literature)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                120 mg/kg daily in 2&#8211;4 divided doses for 14&#8211;21 days, oral route preferred for children.</li>
              <li class="dose child"><strong>For children </strong><br/>
                120 mg/kg daily in 2&#8211;4 divided doses for 14&#8211;21 days, oral route preferred for children.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of <ph outputclass="organism"> <i>Pneumocystis jirovecii</i> </ph> (<ph outputclass="organism"> <i>Pneumocystis carinii</i> </ph> ) infections</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                960 mg once daily, reduced if not tolerated to 480 mg once daily, alternatively 960 mg once daily on alternate days, alternate day dose to be given 3 times weekly, alternatively 960 mg twice a day on alternate days, alternate day dose to be given 3 times weekly.</li>
              <li class="dose child"><strong>For children </strong><br/>
                450 mg/m2 twice daily (max. per dose 960 mg twice daily) for 3 days of the week (either consecutively or on alternate days), dose regimens may vary, consult local guidelines.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>480&#8239;mg of co-trimoxazole consists of sulfamethoxazole 400&#8239;mg and trimethoprim 80&#8239;mg. </p>
            </section>
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Sulfamethoxazole and trimethoprim are used in combination (as <b>co-trimoxazole</b>) because of their synergistic activity (the importance of the sulfonamides has decreased as a result of increasing bacterial resistance and their replacement by antibacterials which are generally more active and less toxic).</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Teratogenic risk in first trimester (trimethoprim a folate antagonist).</p><p>Neonatal haemolysis and methaemoglobinaemia in third trimester; fear of increased risk of kernicterus in neonates appears to be unfounded.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid in severe liver disease.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">In adults</h3>
              <p>Use half normal dose if eGFR 15&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">In children</h3>
              <p>Use half normal dose if estimated glomerular filtration rate 15&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
        
            <section class="generalInformation">
              <h3 class="specificity">In adults</h3>
              <p>Avoid if eGFR less than 15&#8239;mL/minute/1.73&#8239;m<sup>2</sup> and if plasma-sulfamethoxazole concentration cannot be monitored.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">In children</h3>
              <p>Avoid if estimated glomerular filtration rate less than 15&#8239;mL/minute/1.73&#8239;m<sup>2</sup> and if plasma-sulfamethoxazole concentration cannot be monitored.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li><xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref></li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Diarrhoea, headache, hyperkalaemia, nausea, rash,
              </p>
              <p>
                <strong>uncommon:</strong> Vomiting,
              </p>
              <p>
                <strong>rare:</strong> Agranulocytosis, bone marrow depression,
              </p>
              <p>
                <strong>veryRare:</strong> Anorexia, antibiotic-associated colitis, arthralgia, aseptic meningitis, ataxia, blood disorders, convulsions, cough, depression, eosinophilia, glossitis, hallucinations, hepatic necrosis, hypoglycaemia, hyponatraemia, interstitial nephritis, jaundice, leucopenia, liver damage, megaloblastic anaemia, myalgia, myocarditis, pancreatitis, peripheral neuropathy, photosensitivity, pulmonary infiltrates, renal disorders, shortness of breath, Stevens-Johnson syndrome, stomatitis, systemic lupus erythematosus, thrombocytopenia, tinnitus, toxic epidermal necrolysis, uveitis, vasculitis, vertigo,
              </p>
              <p>
                <strong>notKnown:</strong> Rhabdomyolysis reported in HIV-infected patients,
              </p>
        
        
            <section class="advice">
                <h3>Blood disorders or rash</h3>
              <p>Co-trimoxazole is associated with rare but serious side effects. Discontinue immediately if blood disorders (including leucopenia, thrombocytopenia, megaloblastic anaemia, eosinophilia) or rash (including Stevens-Johnson syndrome, toxic epidermal necrolysis, photosensitivity) develop.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For intermittent <i>intravenous infusion</i>, may be further diluted in glucose 5% and 10% or sodium chloride 0.9%. Dilute contents of 1 ampoule (5&#8239;mL) to 125&#8239;mL, 2 ampoules (10&#8239;mL) to 250&#8239;mL or 3 ampoules (15&#8239;mL) to 500&#8239;mL; suggested duration of infusion 60&#8211;90 minutes (but may be adjusted according to fluid requirements); if fluid restriction necessary, 1 ampoule (5&#8239;mL) may be diluted with 75&#8239;mL glucose 5% and the required dose infused over max. 60 minutes; check container for haze or precipitant during administration. In severe fluid restriction may be given undiluted via a central venous line.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i> (<i>Septrin</i>
            <tm tmtype="reg"/>
            <i>for infusion</i>), give intermittently <i>in</i> Glucose 5% or 10% <i>or</i> Sodium chloride 0.9%. Dilute contents of 1 ampoule (5&#8239;mL) to 125&#8239;mL, 2 ampoules (10&#8239;mL) to 250&#8239;mL or 3 ampoules (15&#8239;mL) to 500&#8239;mL; suggested duration of infusion 60&#8211;90 minutes (but may be adjusted according to fluid requirements); if fluid restriction necessary, 1 ampoule (5&#8239;mL) may be diluted with 75&#8239;mL glucose 5% and infused over max. 60 minutes.</p>
            </section>
      </section>



      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>Restrictions on the use of co-trimoxazole</h3>
              <p>Co-trimoxazole is the drug of choice in the prophylaxis and treatment of <ph outputclass="organism">
            <i>Pneumocystis jirovecii</i>
            </ph> (<ph outputclass="organism">
            <i>Pneumocystis carinii</i>
            </ph>) pneumonia; it is also indicated for nocardiasis, <ph outputclass="organism">
            <i>Stenotrophomonas maltophilia</i>
            </ph> infection [unlicensed indication], and toxoplasmosis. It should only be considered for use in acute exacerbations of chronic bronchitis and infections of the urinary tract when there is bacteriological evidence of sensitivity to co-trimoxazole and good reason to prefer this combination to a single antibacterial; similarly it should only be used in acute otitis media in children when there is good reason to prefer it. Co-trimoxazole is also used for the treatment of infections caused by <ph outputclass="organism">
            <i>Burkholderia cepacia</i>
            </ph> in cystic fibrosis [unlicensed indication].</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Asthma
          </li>
          <li>
            avoid in blood disorders (unless under specialist supervision)
          </li>
          <li>
            avoid in infants under 6 weeks (except for treatment or prophylaxis of pneumocystis pneumonia) because of the risk of kernicterus
          </li>
          <li>
              <strong>:</strong>
            elderly (increased risk of serious side-effects) in adults
          </li>
          <li>
            G6PD deficiency (risk of haemolytic anaemia)
          </li>
          <li>
            maintain adequate fluid intake
          </li>
          <li>
            predisposition to folate deficiency
          </li>
          <li>
              <strong>:</strong>
            predisposition to hyperkalaemia in adults
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

          <h3>Therapeutic drug monitoring</h3>
        
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">In children</h3>
              <p>Plasma concentration monitoring may be required with high doses; seek expert advice.</p>
            </section>
        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor blood counts on prolonged treatment.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Not licensed for use in children under 6 weeks.</p>
            </section>
            <section class="unlicensedUse">
              <p>Not licensed for <ph outputclass="organism">
            <i>Burkholderia cepacia</i>
            </ph> infections in cystic fibrosis.</p><p>Not licensed for <ph outputclass="organism">
            <i>Stenotrophomonas maltophilia</i>
            </ph> infections.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Co-trimoxazole is a mixture of trimethoprim and sulfamethoxazole (sulphamethoxazole) in the proportions of 1 part to 5 parts.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in adults</h3>
              <p>Flavours of oral liquid formulations may include vanilla.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>Flavours of oral liquid formulations may include banana, or vanilla.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of CO-TRIMOXAZOLE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP75167"><a href="../medicinalForm/PHP75167.html" data-target="#PHP75167" data-action="load">Tablet</a></div>
            <div id="PHP75175"><a href="../medicinalForm/PHP75175.html" data-target="#PHP75175" data-action="load">Oral suspension</a></div>
            <div id="PHP75182"><a href="../medicinalForm/PHP75182.html" data-target="#PHP75182" data-action="load">Solution for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
